[Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase].
The efficacy and safety of sulbactam/cefoperazone (SBT/CPZ) were evaluated in 42 patients with respiratory tract infections, including pneumonia (29 patients) and lower respiratory tract infections (5 patients). Overall clinical efficacy rates (excellent + good) were 79% in pneumonia and 80% in respiratory tract infections in 34 patients evaluated for clinical efficacy. It was excellent that the clinical efficacy rate was 92% in mild and moderate pneumonia. Pathogens isolated from sputa were 31 strains, including 8 strains of Pseudomonas aeruginosa, 7 of Streptococcus pneumoniae, 3 of Staphylococcus aureus and 3 of Haemophilus influenzae. Since the isolates were eradicated in 18 strains, replaced in 3, unchanged in 2 and unknown in 8, the overall eradication rate was 91%. The eradication rates were 89% in beta-lactamase producing strains and 100% in beta-lactamase positive sputum, and excellent or good in 19 (83%) of 23 patients with beta-lactamase negative sputum. The eradication rate was 88% in 5 patients with beta-lactamase positive sputum. One patient experienced a moderate rash. Abnormal laboratory test values were observed in 10 patients (26.3%), but these abnormalities were mild and transient. These results suggested that SBT/CPZ was effective and safe for the treatment of respiratory tract infections caused by beta-lactamase producing as well as beta-lactamase non-producing bacteria.
Koga
H
H
Second Department of Internal Medicine, Nagasaki University School of Medicine.
Tomono
K
K
Hirakata
Y
Y
Kohno
S
S
Abe
K
K
Kawamoto
S
S
Kusano
S
S
Tanaka
K
K
Morikawa
N
N
Sugiyama
H
H
Katsumata
T
T
Sasayama
K
K
Shimoguchi
K
K
Hashimoto
A
A
Matsumoto
Y
Y
Inoue
Y
Y
Ishiguro
M
M
Hori
H
H
Mashimoto
H
H
Dotsu
Y
Y
Tanaka
H
H
Imamura
Y
Y
Kanda
T
T
Hara
K
K
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001419:Bacteria / Q000201:enzymology / Q000302:isolation & purification; D002438:Cefoperazone / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D013407:Sulbactam / Q000627:therapeutic use; D001618:beta-Lactamases / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D002438:Cefoperazone; D001618:beta-Lactamases; D013407:Sulbactam